KK
ACRS icon

Kotler Kevin’s Aclaris Therapeutics ACRS Stock Holding History

Kotler Kevin’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.13M Buy
+1,705,929
New +$4.31M 1.2% 12

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kotler Kevin's ACRS Position: Q4 2025 in Review

Kotler Kevin opened a new position in Aclaris Therapeutics (ACRS) in Q4 2025: 1,705,929 shares worth $5.13M. The stake represents 1.2% of the portfolio and ranks #12 among its holdings.

122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Kotler Kevin held 1,705,929 shares of Aclaris Therapeutics worth $5.13M as of Q4 2025.
  • Aclaris Therapeutics was a new Kotler Kevin position in Q4 2025.
  • Aclaris Therapeutics made up 1.2% of Kotler Kevin's portfolio in Q4 2025, its #12 holding.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Kotler Kevin's 13F filing for Q4 2025, filed 17 Feb 2026.